Richard L. Wasserman

Dr. Richard L. Wasserman


Research Focus & Metrics

Academic Career Length

50Years (1977-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
RWRichard L. Wasserman
Richard L. Wasserman
AHAngela R. Hague
Angela R. Hague
DPDeanna M. Pence
Deanna M. Pence
RSRobert W. Sugerman
Robert W. Sugerman
SSStacy K. Silvers
Stacy K. Silvers
MHMorley Herbert
Morley Herbert

1 January 2014 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
RWRichard L. Wasserman
Richard L. Wasserman
JFJeffrey M. Factor
Jeffrey M. Factor
JBJames W. Baker
James W. Baker
LMLyndon E. Mansfield
Lyndon E. Mansfield
YKYitzhak Katz
Yitzhak Katz
AEArnon Elizur
Arnon Elizur


5 September 2017 in Immunotherapy
Verified
Journal Article
Open access
RWRichard L. Wasserman
Richard L. Wasserman
Most primary immunodeficiency diseases (PIDDs) resulting in antibody deficiency require intravenous or subcutaneous immunoglobulin G (SCIG) replacement therapy. The flow and distribution of SCIG to the vasculature is impeded by the glycosaminoglycan hyaluronan in the extracellular matrix, which limits the infusion rate and volume per site, necessitating frequent infusions and multiple infusion sites. Hyaluronidase depolymerizes hyaluronan and is a spreading factor for injectable biologics. Recombinant human hyaluronidase (rHuPH20) increases SCIG absorption and dispersion. In patients with PIDD, SCIG facilitated with rHuPH20 (IGHy) has been shown to prevent infections, be well-tolerated and reduce infusion frequency and number of infusion sites as compared with conventional SCIG. This article reviews IGHy clinical studies and real-world practice data in patients with PIDD.

1 June 2011 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
RWRichard L. Wasserman
Richard L. Wasserman
IMIsaac Melamed
Isaac Melamed
RNRobert P. Nelson
Robert P. Nelson
AKAlan P. Knutsen
Alan P. Knutsen
MFMary Beth Fasano
Mary Beth Fasano
JCJoseph A. Church
Joseph A. Church

6 March 2012 in Journal of Clinical Immunology
Verified
Journal Article
Open access
PDF file
RWRichard L. Wasserman
Richard L. Wasserman
JCJoseph A. Church
Joseph A. Church
MSMark Stein
Mark Stein
JMJames Moy
James Moy
MWMartha White
Martha White
SRSyed M. Rehman
Syed M. Rehman
Introduction An investigational 10% liquid intravenous immunoglobulin (IVIG) was studied in 63 patients with primary immunodeficiency (PID) at 15 study sites. Methods Patients were treated every 3 or 4 weeks with 254–1029 mg/kg/infusion of IVIG. Results Overall, Biotest-IVIG infusions were well tolerated. The proportion of infusions that were associated with adverse events during infusion, and up to 72 h after infusion, including those unrelated to study product, was 27.7% with an upper 95% confidence limit ≤30.6%. Two serious bacterial infections (SBIs) were observed resulting in a serious bacterial infection rate of 0.035 per person per year and an upper one-sided 99% confidence limit of ≤0.136 SBI/patient/year. The number of days of work or school missed due to infection were relatively low at 2.28 days/patient/year. Two patients were hospitalized for infection producing a rate of 0.21 hospitalization days/patient/year. The IgG half-life was approximately 30 days with variation among individuals. Conclusions Pharmacokinetic parameters of specific antibody activities were essentially the same as those of total IgG. Biotest-IVIG is safe and effective in the treatment of PID.